Triple-negative carcinomas represent 15–20% of tumors in women with breast cancer, have a relatively poor outcome, and are refractory to hormone and epidermal growth factor receptor type 2 (HER2) therapies (45). This evidence concerns the gene ERBB2 and carcinoma.